-
Je něco špatně v tomto záznamu ?
Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core
M. Sisa, M. Dvorakova, V. Temml, V. Jarosova, T. Vanek, P. Landa
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- benzochinony chemie MeSH
- inhibitory cyklooxygenasy chemická syntéza chemie farmakologie MeSH
- inhibitory lipoxygenas chemická syntéza chemie farmakologie MeSH
- katalytická doména MeSH
- oxidace-redukce MeSH
- počítačová simulace MeSH
- resorcinoly chemie MeSH
- simulace molekulového dockingu MeSH
- spektrální analýza metody MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Publikační typ
- časopisecké články MeSH
Based on the significant anti-inflammatory activity of natural quinone primin (5a), series of 1,4-benzoquinones, hydroquinones, and related resorcinols were designed, synthesized, characterized and tested for their ability to inhibit the activity of cyclooxygenase (COX-1 and COX-2) and 5-lipoxygenase (5-LOX) enzymes. Structural modifications resulted in the identification of two compounds 5b (2-methoxy-6-undecyl-1,4-benzoquinone) and 6b (2-methoxy-6-undecyl-1,4-hydroquinone) as potent dual COX/5-LOX inhibitors. The IC50 values evaluated in vitro using enzymatic assay were for compound 5b IC50 = 1.07, 0.57, and 0.34 μM and for compound 6b IC50 = 1.07, 0.55, and 0.28 μM for COX-1, COX-2, and 5-LOX enzyme, respectively. In addition, compound 6d was identified as the most potent 5-LOX inhibitor (IC50 = 0.14 μM; reference inhibitor zileuton IC50 = 0.66 μM) from the tested compounds while its inhibitory potential against COX enzymes (IC50 = 2.65 and 2.71 μM for COX-1 and COX-2, respectively) was comparable with the reference inhibitor ibuprofen (IC50 = 4.50 and 2.46 μM, respectively). The most important structural modification leading to increased inhibitory activity towards both COXs and 5-LOX was the elongation of alkyl chain in position 6 from 5 to 11 carbons. Moreover, the monoacetylation in ortho position of bromo-hydroquinone 13 led to the discovery of potent (IC50 = 0.17 μM) 5-LOX inhibitor 17 (2-bromo-6-methoxy-1,4-benzoquinone) while bromination stabilized the hydroquinone form. Docking analysis revealed the interaction of compounds with Tyr355 and Arg120 in the catalytic site of COX enzymes, while the hydrophobic parts of the molecules filled the hydrophobic substrate channel leading up to Tyr385. In the allosteric catalytic site of 5-LOX, compounds bound to Tyr142 and formed aromatic interactions with Arg138. Taken together, we identified optimal alkyl chain length for dual COX/5-LOX inhibition and investigated other structural modifications influencing COX and 5-LOX inhibitory activity.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019977
- 003
- CZ-PrNML
- 005
- 20210830101556.0
- 007
- ta
- 008
- 210728s2020 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2020.112620 $2 doi
- 035 __
- $a (PubMed)32738413
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Sisa, Miroslav $u Laboratory of Plant Biotechnologies, Institute of Experimental Botany of the Czech Academy of Sciences, Rozvojova 263, 165 02 Prague 6, Lysolaje, Czech Republic
- 245 10
- $a Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core / $c M. Sisa, M. Dvorakova, V. Temml, V. Jarosova, T. Vanek, P. Landa
- 520 9_
- $a Based on the significant anti-inflammatory activity of natural quinone primin (5a), series of 1,4-benzoquinones, hydroquinones, and related resorcinols were designed, synthesized, characterized and tested for their ability to inhibit the activity of cyclooxygenase (COX-1 and COX-2) and 5-lipoxygenase (5-LOX) enzymes. Structural modifications resulted in the identification of two compounds 5b (2-methoxy-6-undecyl-1,4-benzoquinone) and 6b (2-methoxy-6-undecyl-1,4-hydroquinone) as potent dual COX/5-LOX inhibitors. The IC50 values evaluated in vitro using enzymatic assay were for compound 5b IC50 = 1.07, 0.57, and 0.34 μM and for compound 6b IC50 = 1.07, 0.55, and 0.28 μM for COX-1, COX-2, and 5-LOX enzyme, respectively. In addition, compound 6d was identified as the most potent 5-LOX inhibitor (IC50 = 0.14 μM; reference inhibitor zileuton IC50 = 0.66 μM) from the tested compounds while its inhibitory potential against COX enzymes (IC50 = 2.65 and 2.71 μM for COX-1 and COX-2, respectively) was comparable with the reference inhibitor ibuprofen (IC50 = 4.50 and 2.46 μM, respectively). The most important structural modification leading to increased inhibitory activity towards both COXs and 5-LOX was the elongation of alkyl chain in position 6 from 5 to 11 carbons. Moreover, the monoacetylation in ortho position of bromo-hydroquinone 13 led to the discovery of potent (IC50 = 0.17 μM) 5-LOX inhibitor 17 (2-bromo-6-methoxy-1,4-benzoquinone) while bromination stabilized the hydroquinone form. Docking analysis revealed the interaction of compounds with Tyr355 and Arg120 in the catalytic site of COX enzymes, while the hydrophobic parts of the molecules filled the hydrophobic substrate channel leading up to Tyr385. In the allosteric catalytic site of 5-LOX, compounds bound to Tyr142 and formed aromatic interactions with Arg138. Taken together, we identified optimal alkyl chain length for dual COX/5-LOX inhibition and investigated other structural modifications influencing COX and 5-LOX inhibitory activity.
- 650 _2
- $a benzochinony $x chemie $7 D016227
- 650 _2
- $a katalytická doména $7 D020134
- 650 _2
- $a počítačová simulace $7 D003198
- 650 _2
- $a inhibitory cyklooxygenasy $x chemická syntéza $x chemie $x farmakologie $7 D016861
- 650 _2
- $a inhibitory lipoxygenas $x chemická syntéza $x chemie $x farmakologie $7 D016859
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a oxidace-redukce $7 D010084
- 650 _2
- $a resorcinoly $x chemie $7 D012118
- 650 _2
- $a spektrální analýza $x metody $7 D013057
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dvorakova, Marcela $u Laboratory of Plant Biotechnologies, Institute of Experimental Botany of the Czech Academy of Sciences, Rozvojova 263, 165 02 Prague 6, Lysolaje, Czech Republic
- 700 1_
- $a Temml, Veronika $u Department of Pharmacy/Pharmacognosy and Center of Molecular Biosciences (CMBI), University of Innsbruck, Innrain 80-82, 6020, Innsbruck, Austria
- 700 1_
- $a Jarosova, Veronika $u Laboratory of Plant Biotechnologies, Institute of Experimental Botany of the Czech Academy of Sciences, Rozvojova 263, 165 02 Prague 6, Lysolaje, Czech Republic; Department of Food Science, Faculty of Agrobiology, Food and Natural Resources, The Czech University of Life Sciences Prague, Kamycka 129, 165 21 Prague 6, Suchdol, Czech Republic
- 700 1_
- $a Vanek, Tomas $u Laboratory of Plant Biotechnologies, Institute of Experimental Botany of the Czech Academy of Sciences, Rozvojova 263, 165 02 Prague 6, Lysolaje, Czech Republic
- 700 1_
- $a Landa, Premysl $u Laboratory of Plant Biotechnologies, Institute of Experimental Botany of the Czech Academy of Sciences, Rozvojova 263, 165 02 Prague 6, Lysolaje, Czech Republic. Electronic address: landa@ueb.cas.cz
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 204, č. - (2020), s. 112620
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32738413 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101556 $b ABA008
- 999 __
- $a ok $b bmc $g 1690714 $s 1140423
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 204 $c - $d 112620 $e 20200711 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20210728